Skip to main content
TB

Trebe Biotech

Trebe Biotech utilizes insect larvae as biofactories to produce high-quality recombinant proteins and vaccines, offering a sustainable and cost-effective alternative to traditional bioreactor methods. This approach addresses the need for rapid production of bioproducts, particularly in response to emerging health challenges in both human and veterinary medicine.

Pergamino, ArgentinaFounded 20204700+ followers
Updated 20 months ago

Funding

$530K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

S
Funding rounds are not available yet.

Founders

Product

Problem

Traditional bioreactor methods for producing recombinant proteins and vaccines can be expensive, slow to scale, and may not be suitable for rapid responses to emerging health challenges. These limitations hinder the development and production of critical bioproducts for both human and veterinary medicine.

Solution

Trebe Biotech leverages insect larvae as biofactories to produce high-value recombinant proteins and vaccines, offering a sustainable and cost-effective alternative to conventional bioreactor systems. This innovative platform utilizes the rapid growth and high-density living capabilities of insects to efficiently generate bioproducts. The platform's versatility allows for quick adjustments in production to meet emergency vaccine needs or to develop custom proteins for novel treatments. By harnessing the power of insects, Trebe Biotech aims to expand the availability of innovative treatments and vaccines, particularly in the veterinary field, and to develop rapid diagnostic tools for tackling epidemics.

Target Audience

The primary target audience includes veterinary labs seeking innovative treatments and vaccines, as well as organizations requiring rapid diagnostic tools for disease identification and epidemic management.

Features

  • Insect larvae-based biofactories for recombinant protein and vaccine production
  • Rapid scalability to meet emergency vaccine demands
  • Adaptable platform for developing custom proteins
  • Cost-effective alternative to traditional bioreactor methods
  • Sustainable biomanufacturing process
This profile is AI-generated and may contain inaccuracies.